

ASTRO 2018 – NRG Oncology Presentation Schedule
Oral Presentations, ePoster Discussions, and Poster Presentations
October 21 - 24, 2018 – Henry B. Gonzalez Convention Center

Disease Site & Study #	Sunday October 21, 2018	Time/Location
Prostate NRG/TOG 0521	The influence of the pretreatment host immune inflammatory state and response to radiation therapy in high risk adenocarcinoma of the prostate: a validation study from NRG Oncology/TOG 0521 Presenter: William Hall Abstract #: 25	1:15 PM – 2:45 PM Biology 1 - Innovative Biologic Approaches to Improve Risk Stratification and Treatment Outcomes Location: Room 008 Discussion: 1:45 PM - 1:55 PM CME: 1.50
Prostate NRG/TOG 0232	Patient reported outcomes of NRG Oncology/TOG 0232: a phase III study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone in intermediate risk prostate cancer Presenter: Deborah Bruner Abstract #: 3	3:15 PM - 4:45 PM Clinical Trials Session Location: Stars at Night Ballroom Discussion: 3:45 PM - 3:55 PM CME: 1.50
Breast NRG/TOG 9804	Randomized trial evaluating radiation following surgical excision for "Good Risk" DCIS: 12-year report from NRG/TOG 9804 Presenter: Beryl McCormick Abstract #: LBA1	3:15 PM - 4:45 PM Clinical Trials Session Location: Stars at Night Ballroom Discussion: 3:55 PM – 4:05 PM CME: 1.50
Disease Site & Study #	Monday October 22, 2018	Time/Location
Prostate NRG/TOG 9408	Long term update of NRG Oncology TOG 9408 Presenter: Christopher Jones Abstract #: 62	7:45 AM-9:00 AM GU 2 - Long-Term Updates of Prospective Prostate Cancer Clinical Trials Location: Room 214 C/D Discussion: 8:15 AM - 8:25 AM CME: 1.25
Brain NRG/TOG 9813	Elevated MGMT gene expression is independently associated with worse overall survival in NRG Oncology/TOG 9813: a phase III study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) in anaplastic grade III glioma Presenter: Jessica Fleming Abstract #: 92	10:45 AM – 12:15 PM CNS 2 – Gliomas Location: Room 004 Discussion: 10:45 AM - 10:55 AM CME: 1.50
Breast NRG/TOG 1014	NRG Oncology/TOG 1014: patient reported outcomes (PRO) and cosmesis from a phase II study of repeat breast preserving surgery and 3D conformal (3D-CRT) partial breast re-irradiation (PBri) for in-breast recurrence. Presenter: Douglas Arthur Abstract #: 84	10:45 AM-12:15 PM Breast 1 - Toxicity Location: Room 214 C/D Discussion: 10:55 AM - 11:05 AM CME: 1.50
Head Neck NRG/TOG 1016	NRG-TOG 1016: phase III trial comparing radiation/cetuximab to radiation/cisplatin in HPV-related cancer of the oropharynx Presenter: Andy Trotti Abstract #: LBA4	2:15 PM - 3:45 PM Plenary Session Location: Stars at Night Ballroom Discussion: 2:35 PM - 2:45 PM CME: 1.50
Prostate Meta-Analysis of TOG Trials	Androgen Receptor Activity and Radiotherapeutic Sensitivity in African-American Men With Prostate Cancer: A Large Scale Gene Expression Analysis and Meta-Analysis of TOG Trials Presenter: Daniel Spratt	2:15 PM – 3:45 PM Plenary Session Location: Stars at Night Ballroom Discussion: 2:55 PM – 3:05 PM CME: 1.50

Prostate NRG/RTOG 0534	Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG Oncology/RTOG 0534 SPPORT Trial Presenter: Alan Pollack Abstract #: LBA5	2:15 PM - 3:45 PM Plenary Session Location: Stars at Night Ballroom Discussion: 3:15 PM - 3:25 PM CME: 1.50
-------------------------------	--	--

Disease Site & Study #	Tuesday October 23, 2018	Time/Location
Brain NRG-CC001	Preservation of neurocognitive function (NCF) with conformal avoidance of the hippocampus during whole-brain radiotherapy (HA-WBRT) for brain metastases: preliminary results of phase III trial NRG Oncology CC001 Presenter: Vinai Gondi Abstract #: LBA9	7:45 AM - 9:00 AM Late-Breaking Abstracts Special Session Location: Room 007 C/D Discussion: 7:45 AM - 7:55 AM CME: 1.25
Breast NRG-BR001	Phase I trial of stereotactic body radiotherapy (SBRT) to multiple metastatic sites: a NRG Oncology study Presenter: Steven Chmura Abstract #: 136	7:45 AM - 9:00 AM Breast 2 - Biology and SBRT Session Location: Room 214 A/B Discussion: 8:25 AM - 8:35 AM CME: 1.25
Lung NRG/RTOG 0617	The role of heart-related dose-volume metrics on overall survival in the RTOG 0617 clinical trial. Presenter: Maria Thor Abstract #: 195	2:45 PM - 4:15 PM Physics 7 - Special Session: Outcome Analysis and Modeling Location: Room 214 C/D Discussion: 3:35 PM - 3:45 PM CME: 1.50
Disease Site & Study #	Wednesday October 24, 2018	Time/Location
Gynecologic NRG/RTOG 1203	Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: a patient reported outcome study of RTOG 1203 Presenter: Andre Konski Abstract #: 324	3:15 PM – 4:45 PM HSR 2 – Health Services Research Location: Room 008 Discussion: 3:35 PM - 3:45 PM CME: 1.50